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Abstract B cells provide immunity to extracellular pathogens by secreting a
diverse repertoire of antibodies with high affinity and specificity for exposed
antigens. The B cell receptor (BCR) is a transmembrane antibody, which facilitates
the clonal selection of B cells producing secreted antibodies of the same specificity.
The diverse antibody repertoire is generated by V(D)J recombination of heavy and
light chain genes, whereas affinity maturation is mediated by activation-induced
cytidine deaminase (AID)-mediated mutagenesis. These processes, which are
essential for the generation of adaptive humoral immunity, also render B cells
susceptible to chromosomal rearrangements and point mutations that in some cases
lead to cancer. In this chapter, we will review the central role of PI3Ks in mediating
signals from the B cell receptor that not only facilitate the development of func-
tional B cell repertoire, but also support the growth and survival of neoplastic B
cells, focusing on chronic lymphocytic leukemia (CLL) B cells. Perhaps because of
the central role played by PI3K in BCR signaling, B cell leukemia and lymphomas
are the first diseases for which a PI3K inhibitor has been approved for clinical use.
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1 PI3K Family
The PI3Ks are an ancient family of intracellular kinases that initially evolved to
mediate nutrient sensing and metabolic control. In mammals, there are 8 different
PI3K catalytic subunits, divided into three classes. Class I PI3Ks phosphorylate
phosphatidylinositol(4,5)P2 (PIP2) to generate phosphatidylinositol (3,4,5)P3 (PIP3)
which acts as pivotal second messenger signaling molecule. In B cells, both Akt
and Btk can bind to PIP3 via their PH domains. PIP3 is essential for the activation of
Akt and contributes to the activation of Btk. Less is known about the role of the
classes II and III PI3Ks in B cells (Hawkins and Stephens 2015; Okkenhaug
2013b).
Mammals have 4 different class I PI3Ks. Heterodimers of a regulatory subunit
(p85α, p55α, p50α, p85β, or p55γ, collectively referred to as p85) and a catalytic
subunit (p110α, p110β, or p110δ) form PI3Kα, PI3Kβ, or PI3Kδ whereas PI3Kγ is
a heterodimer of p101 or p84 with p110γ. The p85 regulatory subunits contain SH2
domains that recruit PI3K to tyrosine-kinase-linked receptors and their substrates.
The p101 and p84 regulatory subunits bind Gβγ subunits released upon G-protein-
coupled receptor activation. PI3Kβ can be recruited to tyrosine phosphorylated
proteins either via its associated p85 subunit or by direct interaction with Gβγ
subunits which bind a unique sequence within the p110 protein (Dbouk et al. 2012).
B cells express high levels of PI3Kδ, low levels of PI3Kα and PI3Kγ, and almost no
PI3Kβ. PI3Kα and PI3Kδ act redundantly during early B cell development in the
bone marrow, whereas PI3Kδ is dominant in mature B cells (Ramadani et al. 2010).
PI3K signaling is antagonized by the lipid phosphatases Pten and Ship, which
remove the 3 and 5 phosphates from PIP3, respectively, and act together to prevent
PI3K-dependent B cell transformation (Miletic et al. 2010) (Fig. 1).
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2 Mechanism of PI3K Signaling in B Cells
2.1 Activation of PI3K by the BCR and CD19
In mature B cells, PI3Kδ is chiefly responsible for PIP3 generation and Akt acti-
vation (Bilancio et al. 2006; Clayton et al. 2002; Okkenhaug et al. 2002). The best
characterized mechanism for regulation of PI3K in B cells involves phosphorylation
of the receptor CD19 within two YxxM motifs that bind the p85 SH2 domains with
high affinity (Tuveson et al. 1993; Wang et al. 2002) (Fig. 1). CD19 lacks intrinsic
or associated tyrosine kinase activity; instead, tyrosine kinases associated with the
B cell receptor are mainly responsible for CD19 activation (Buhl and Cambier
1999). Hence, the BCR activates CD19 in trans to recruit PI3K. Consistent with this
finding, there are many similarities between mice lacking CD19 and mice lacking
p110δ expression in B cells, such as the lack of marginal zone B cells and impaired
T-cell-independent immune responses. The membrane-associated protein BCAP
Fig. 1 Activation of PI3K in B cells. PI3Kδ is a central integrator of signals from the BCR, CD19,
CXCR4, CXCR5, and BAFF in B cells. The precise mechanisms linking chemokine and FAFF
receptors to PI3K signaling have yet to be fully elucidated. PI3K signaling is antagonized by
PTEN and by SHIP which associates with the negative regulator FcγRIIB. PIP3 and its metabolite
PI(3,4)P2 can both activate Akt and its downstream effector, including the inactivation of FOXO.
By contrast, BTK can only bind PIP3. Not shown in this figure is the complex cross regulation
between PI3K and mTOR which is described in the main text and elsewhere
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can also bind and recruit PI3K via p85, but is not essential for PI3K activity in
mature B cells (Yamazaki et al. 2002). Rather, there appears to be redundancy
between CD19 and BCAP during early B cell development (Aiba et al. 2008).
The BCR is coupled to BCAP via the adapter protein Nck (Castello et al. 2013).
2.2 Atypical Activation of PI3Kδ by Chemokine Receptors
in B Cells
B cells are unusual in that PI3Kδ is also the dominant isoform activated by
G-protein-coupled receptors (GPCRs) such as the chemokine receptor CXCR5
(Reif et al. 2004). In other cell types, chemokine receptors typically activate PI3Kγ
(Andrews et al. 2007). The mechanism underpinning this unusual coupling in B
cells remains undefined, but is in part also shared with NK cells (Saudemont et al.
2009). As a consequence, PI3Kγ-deficient B cells are phenotypically normal.
2.3 BAFF Signals via PI3K to Promote B Cell Survival
BAFF provides an essential survival signal for immature and mature splenic B cells.
The BAFF receptor is a member of the TNFR superfamily, which contributes to the
activation of NF-κB via the TRAF3-NIK IKK pathway (Mackay et al. 2010;
Rickert et al. 2011). Surprisingly, however, deletion of IKK in B cells did not
mimic all the severe loss of mature B cells observed in BAFF-R-deficient mice
(Jellusova et al. 2013). However, BAFF-dependent cell survival in PI3Kδ null B
cells was impaired (Henley et al. 2008), and loss of Pten was sufficient to rescue B
cell survival in a BAFF-deficient background (Jellusova et al. 2013). BAFF stim-
ulation results in Akt phosphorylation, and p110δ can be found associate with the
BAFF-R (Patke et al. 2006). However, maximal Akt phosphorylation in response to
BAFF stimulation was delayed and suggested it may occur downstream of NF-κB
activation as Akt phosphorylation after 24 h of stimulation with BAFF was
defective in Ikk1−/− B cells (Otipoby et al. 2008). By contrast, Schweighofer and
colleagues noted that in Syk-deficient B cells, BAFF-R failed to promote survival
and proposed a model whereby BAFF-R engages to BCR signaling complex to
activate PI3K since Pten deletion rescued survival signals in B cells lacking Syk
(Schweighoffer et al. 2013). Similar results were reported by Hobeika and col-
leagues; however, the latter study provided evidence also for BAFF-dependent, but
Syk-independent survival pathway involving CD19 and PI3K (Hobeika et al.
2015). These results may be reconciled by a model in which BAFF stimulates the
activity of a BCR-associated Src-family kinase (SFK) which can phosphorylate the
BCR-associated Igα and Igβ, leading to the recruitment of Syk which phosphory-
lates Bcap to recruit PI3K (Fig. 1). SFK can also phosphorylate CD19 leading to
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PI3K recruitment in a Syk-independent manner. The relative role of NF-κB versus
the PI3K pathway in BAFF-R-dependent survival is likely to depend on the stage of
B cell development. Importantly, the transformation of Pten−/−Ship−/− B cells was
independent of BAFF-R (Jellusova et al. 2013). This last result suggests that
blocking BAFF alone is not going to be an effective strategy to treat PI3K-driven B
cell leukemia.
2.4 Pdk1, Akt, and Btk Are PIP3 Binding Proteins in B Cells
Akt is a Ser/Thr kinase which is absolutely dependent on PI3K for its full acti-
vation. Once recruited to a pool of PIP3 at the plasma membrane, Akt becomes
phosphorylated on Thr308 by Pdk1 which is similarly bound by PIP3, but which in
contrast to Akt can also be activated to phosphorylate other substrate in the absence
of PIP3 (Pearce et al. 2010). A major role for Akt in B cells is to phosphorylate and
inactivate Foxo transcription factors (Amin and Schlissel 2008; Dengler et al.
2008). Foxo binds to the promoter for the IL7R, Rag1 and Rag2, Aicda, and other
key regulators of B cell development and differentiation (Alkhatib et al. 2012; Amin
and Schlissel 2008; Dengler et al. 2008). Akt can also contribute to the activation of
mechanistic target of rapamycin (mTOR). mTOR exists in two mutually exclusive
protein complexes referred to as mTORc1 and mTORc2. Of these, only mTORc1 is
inhibited by rapamycin. Akt phosphorylates and inactivates the tuberin proteins
Tsc2 and Tsc1, which in turn negatively regulate mTORc1 activity by suppressing
Rheb (Limon and Fruman 2012). How mTORc2 is activated remains unknown, but
mTORc2 phosphorylates Akt on Ser473, resulting in its full activation. There is
hence a circular dependency between Akt and mTOR (Okkenhaug 2013b).
The PH domain of Btk can also bind PIP3 with high selectivity, but in contrast to
Akt, it is possible to activate Btk under conditions where PI3K activity has been
blocked (Matsuda et al. 2009; Scharenberg and Kinet 1998; Suzuki et al. 2003b).
This may be because Btk also has SH2 domain that can recruit Btk to the adapter
protein Slp65 (Kurosaki 2002). It is possible that PI3K fine-tunes Btk activity
following SH2-mediated recruitment of Btk or that there are particular stimulatory
conditions under which Btk is more PIP3 dependent than others.
3 Role of PI3K in B Cell Development and Function
3.1 PI3Kα and PI3Kδ Act Redundancy in Bone Marrow
B Cells
Mice lacking both PI3Kα and PI3Kδ in B cell experience a complete block in B cell
development shortly after the expression of the immunoglobulin heavy chain
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(Ramadani et al. 2010). These data indicate that PI3K is not required for V(D)J
recombination per se, but rather in order for the pre-BCR formed by the Igh and
surrogate light chains to signal further developmental progression. Individual loss
of PI3Kα or PI3Kδ alone had no consequence at this developmental stage.
Interestingly, loss of Pten or Foxo also causes a block at this developmental stage,
but for different reasons. Pten loss leads to increased PI3K-Akt signaling, which in
turn leads to the exclusion of Foxo from the nucleus. Because Foxo regulates both
IL7R expression and the expression of Rag genes as well as splicing of the
lineage-specifying transcription factor Pax-5, Pten−/− or Foxo−/− cells do not
express essential genes required for developmental progression and Ig gene
recombination (Alkhatib et al. 2012; Amin and Schlissel 2008; Dengler et al. 2008).
3.2 P110δ is the Main PI3K Isoform in Mature B Cells
In mature B cells, complete ablation of BCR-induced Akt phosphorylation is
achieved by inhibiting p85α or p110δ alone, but not by deleting p85β, p110α,
p110β, or p110γ (Okkenhaug 2013a; Okkenhaug and Fruman 2010). Hence, it
appears that the p85α-p110δ heterodimer is preferentially engaged by the BCR. The
reason why PI3Kα is not required for mature B cell activation is unclear, but cannot
be explained by loss of expression of the p110α subunit which expressed similar
levels in immature and mature B cells. Rather, we have speculated that there is a
specific requirement for PI3Kδ during agonist activation of the BCR, but that
so-called “tonic signaling” can occur via either PI3Kα or PI3Kδ (Okkenhaug
2013b; Ramadani et al. 2010). Tonic BCR signaling is essential for the survival of
mature B cells. Therefore, acute ablation of the BCR leads to B cell death in vivo.
However, this death can be prevented by expressing an activated form of p110α in
B cells, or by deleting Pten or Foxo1 (Srinivasan et al. 2009). The key role for
PI3Kδ in BCR signaling means that T-cell-independent immune responses are
strongly attenuated in PI3Kδ-deficient mice (Clayton et al. 2002; Okkenhaug et al.
2002; Rolf et al. 2010). However, T-cell-dependent humoral immune responses are
relatively unaffected by the loss of the p110δ subunit selectively in B cells (Rolf
et al. 2010). This is in part because PI3Kδ actually antagonizes the signals required
for immunoglobulin class switching and affinity maturation and also because sig-
naling via CD40 is independent of PI3Kδ. However, follicular helper T cells do not
develop in absence of PI3Kδ. As a consequence, congenital or T-cell-specific loss
of PI3Kδ leads to attenuated T-cell-dependent humoral immune responses (Rolf
et al. 2010). This raises the important point that some effects observed on B cell
function after administration of PI3Kδ inhibitors may be secondary to their effects
on T cells.
PI3Kδ may also be required for antigen presentation by B cells (Al-Alwan et al.
2007). In addition, IL-21 was shown to selectively stimulate the expression of the
costimulatory receptor CD86 via PI3Kδ (Attridge et al. 2014). The expression of
CD86 by B cells is essential for their ability to solicit help as it provides
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costimulation via CD28 expressed by T cells. It should be noted, however, that
PI3Kδ-deficient B cells can still undergo CSR in the absence of intrinsic PI3Kδ
activity, and moreover, that unrestrained PI3K signaling in Pten−/− B cells antag-
onizes CSR (Janas et al. 2008; Omori et al. 2006; Rolf et al. 2010; Suzuki et al.
2003a). Indeed, PI3Kδ inhibition leads to enhanced CSR to the IgE isotype (Zhang
et al. 2008, 2012). The precise requirement for PI3K during the GC reaction
therefore needs to be fully elucidated, but is likely to depend in part on the
costimulatory and cytokine milieu.
3.3 PI3Kδ Regulates Marginal Zone B Cell Development
Thedevelopment ofmarginalB cells is entirely dependent onPI3Kδ (Okkenhaug et al.
2002; Ramadani et al. 2010). Marginal zone (MZ) B cells secrete mainly IgM or IgG3
which are thought to be broadly protective against microbial antigens, possibly as a
first-linedefence.MZBcells aremaintained in theperipheryof theBcell follicles in the
spleen, and it is possible that PI3Kδ promotes their survival by facilitating adhesion to
the matrix in the marginal zone (Durand et al. 2009). Treatment of mice with a PI3Kδ
inhibitor leads to a gradual depletion of marginal zone B cells from the marginal zone,
but not a complete loss of splenic B cells with amarginal zone like phenotype (Durand
et al. 2009). This dependency on PI3Kδ for MZ B cells to be nurtured by their local
microenvironment may be shared with CLL B cells described next.
4 Chronic Lymphocytic Leukemia
4.1 BCR Signaling in CLL Pathogenesis
CLL is a B cell malignancy characterized by the accumulation of mature,
CD5+CD23+ monoclonal B lymphocytes in the blood, secondary lymphatic tissues,
and the bone marrow (Chiorazzi et al. 2005). CLL is the most common type of
leukemia in adults in Western societies. Several prognostic markers in CLL, such as
somatic mutations in the immunoglobulin (Ig) heavy chain variable gene segments
(IGHV) (Damle et al. 1999; Hamblin et al. 1999), aberrant expression of ZAP-70
(which may act redundantly with SYK) (Chiorazzi 2012), and upregulation of
CCL3 (Sivina et al. 2011), are associated with the function of the BCR, suggesting
a relationship between BCR signaling, disease progression, and inferior prognosis.
Based on the degree of somatic hypermutation of the IGHVs, patients can be
classified as “unmutated” (U-CLL), if they have 98 % or more sequence homology
with the germline sequence, or as “mutated” (M-CLL) cases, if they have less than
98 % sequence homology (Fais et al. 1998). U-CLL cases have a more aggressive
clinical course and shorter survival, whereas M-CLL cases have more indolent
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disease progression and longer survival (Damle et al. 1999; Hamblin et al. 1999).
BCRs in CLL patients characteristically have a bias toward usage of restricted
IGHV and Ig light chain variable gene κ and λ segments (IGLVκ/λ) genes, which
differ from those of normal B cells, leading to remarkably similar, “stereotyped”
third complementarity-determining region of the heavy chain (HCDR3 s) and
somatically mutated IGs (Baliakas et al. 2015; Messmer et al. 2004; Stamatopoulos
et al. 2007), suggesting antigen-driven selection and expansion of CLL clones.
Moreover, recurrent binding of antigen may foster the selection and expansion of B
cells clones during early CLL pathogenesis, even before progression to overt CLL
(Chiorazzi 2012; Chiorazzi and Efremov 2013; Stevenson et al. 2011). Gene
expression profile (GEP) studies revealed that CLL cells from patients with U-CLL
show BCR pathway activation (Rosenwald et al. 2001), and comparative GEP
analyses demonstrated that BCR signaling and NF-κB signaling are the most
prominent pathways activated in CLL cells isolated from lymphatic tissues
(Herishanu et al. 2011), indicating that BCR activation is a key driver for CLL
proliferation within disease-characteristic proliferation centers (also called
pseudo-follicles) in secondary lymphoid tissues.
Two major mechanisms of BCR activation have been described in CLL: ligand
(antigen)-induced and ligand-independent autonomous BCR activation (Burger and
Chiorazzi 2013). In contrast, activating BCR pathway mutations which are common
in diffuse large B cell lymphoma (DLBCL) generally does not appear to play a role
in CLL patients (Philippen et al. 2010), except as a treatment resistance mechanism
in patients receiving BCR-signaling-targeted therapy. In CLL patients developing
ibrutinib resistance, BTK and PLCγ2 mutations have been linked to drug resistance,
causing either ineffective drug binding to its target (C481S mutation of BTK) or
autonomous BCR pathway activation due to gain-of-function mutations (R665W
and L845F mutations in PLCγ2) (Woyach et al. 2014). BCRs from U-CLL patients
are more poly-reactive, whereas BCRs from M-CLL cases are more selective,
providing high-affinity antigen binding. U-CLL BCRs can recognize auto-antigens
and other environmental or microbial antigens (Borche et al. 1990; Broker et al.
1988; Herve et al. 2005; Sthoeger et al. 1989), such as cytoskeletal non-muscle
myosin heavy chain IIA and vimentin, as well as the Fc-tail of IgG (“rheumatoid
factors”), ssDNA, or dsDNA, LPS, apoptotic cells, insulin and oxidized LDH
(Binder et al. 2010; Borche et al. 1990; Catera et al. 2008; Chu et al. 2010; Herve
et al. 2005; Lanemo Myhrinder et al. 2008; Sthoeger et al. 1989). Microbial anti-
gens, such as bacterial and fungal antigens, also can be specifically recognized by
CLL BCR. M-CLL patients express IGHV3-7 with short HCDR3 sequences, which
display high-affinity binding to β-(1,6)-glucan, a major antigenic determinant of
yeasts and filamentous fungi (Hoogeboom et al. 2013). Collectively, these findings
indicate that antigen selection and affinity maturation promote the expansion of
certain CLL clones via antigen-/pathogen-specific BCR signaling, similar to the
role of H. pylori in MALT lymphoma pathogenesis.
In addition, two recent studies demonstrated an additional form of auto-reactive
BCR signaling in CLL termed autonomous BCR signaling (Duhren-von Minden
et al. 2012; Iacovelli et al. 2015). These data are based on experiments in which
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CLL BCRs are expressed by retroviral gene transfer into mouse cells that lack
endogenous BCRs. These CLL BCRs were found to bind via their HCDR3 to an
epitope in the second framework region (FR2) of another antibody, inducing Ca2+
signaling. The finding could explain the presence of phosphorylated LYN and SYK
seen in CLL cells, although it does not appear to account for clinical differences
between M-CLL and U-CLL (Duhren-von Minden et al. 2012) or for the lack of
CLL cell proliferation in the absence of external BCR stimulation (Hoogeboom
et al. 2013). Binder et al. reported an alternative epitope for BCR self-recognition in
CLL, located in the framework region 3 of the variable region of IGH (Binder et al.
2013). Recent mouse model work evaluated these different types of antigen-BCR
interactions in the Eμ-TCL1 transgenic mouse model of CLL. First, the authors
demonstrated that low-affinity BCR interactions with auto-antigens, such as phos-
phatidylcholine (PtC), are positively selected (Chen et al. 2013; Iacovelli et al.
2015); secondly, BCR signaling in response to such antigens accelerated CLL
development, indicating that BCR signaling triggered by external (auto)antigen
increases the aggressiveness of the disease. Finally, ligand-independent autono-
mous signaling of CLL BCRs likely also contributes to the disease process in this
model (Iacovelli et al. 2015).
4.2 Role of Chemokine Signaling in CLL
Besides its role in BCR signaling, PI3Kδ also plays an important role in CLL cell
migration and tissue homing (Fig. 2). Preclinical studies established that PI3Kδ
blockade with idelalisib inhibited CLL cell migration in response to tissue homing
chemokines (CXCL12 and CXCL13) and impaired leukemia cell adhesion and
migration beneath stromal cells that secrete chemokines (Hoellenriegel et al. 2011).
These effects are similar to the effects of BTK inhibition on migration and adhesion
of normal and malignant B cells (de Rooij et al. 2012; Ponader et al. 2012;
Spaargaren et al. 2003) and emphasize that PI3Kδ and BTK share functions in the
transmission of signals from chemokine receptors and adhesion molecules. An
alternative, not mutually exclusive mechanism for explaining the effects of these
kinase inhibitors on B cell trafficking and homing is related directly to the BCR.
Activation of the BCR induces inside-out activation of integrins and reorganization
of the cytoskeleton (Harwood and Batista 2010), involving small GTPases such as
Rac2 and Rap (Arana et al. 2008). Consequently, BCR triggering results in
enhanced integrin-mediated B cell adhesion, which, in turn, can be reversed via
PI3Kδ inhibition with idelalisib, inhibiting integrin-mediated adhesion of CLL B
cells to VCAM1 (CD106) (Fiorcari et al. 2013). These mechanism likely contribute
to the “class effect” of PI3Kδ (Brown et al. 2014; Furman et al. 2014), BTK (Byrd
et al. 2013), and SYK inhibitors (Friedberg et al. 2010) in CLL and MCL patients
(Chang et al. 2013), where a mobilizing effect (“redistribution”) of tissue-resident B
cells into the peripheral blood characteristically is seen during the first months of
therapy (Burger and Montserrat 2013).
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Taking a closer look at the mechanism regulating B cell and CLL cell migration
and tissue homing helps us to understand the complex effects of PI3Kδ blockade in
CLL. Trafficking of normal lymphocytes, but also of CLL cells between blood and
secondary lymphoid tissues, is organized by tissue-specific expression of chemo-
kines and ligand- and activation-regulated expression of chemokine receptors on
lymphocytes, cooperating with adhesion molecules and their ligands (Burger and
Montserrat 2013; Moser and Loetscher 2001). Lymphocytes in the blood interact
with vascular endothelium via adhesion molecules (selectins and integrins) in a
process called rolling. Chemokines on the luminal surface of the endothelium
activate chemokine receptors on these rolling lymphocytes, which in turn causes
integrin activation (Springer 1994), arrest and firm adhesion, followed by trans-
endothelial migration into the tissues, where stromal cells organize the localization
Fig. 2 Cellular and molecular interactions between CLL cells and the tissue microenvironment.
B cell receptor (BCR) signaling is a key pathway for promoting survival and growth of CLL B
cells, mediated via upstream kinases SYK and PI3Kδ, and further downstream signaling detailed
in Fig. 1. In addition, interactions between CLL cells and T cells are central for the expansion of
the malignant CLL clone. Interactions via CD40, expressed on the CLL cells, and CD40 ligand
(CD154), as well as cytokines (IL4, TNFα, IFNγ, CCL3, CCL4), play an important role in
CLL-T-cell cross talk. CLL cells are attracted and retained in tissue microenvironments, such as
the secondary lymphatic tissues and the bone marrow, by chemokines that are constitutively
secreted by tissue mesenchymal stromal cells (MSC) and monocyte-derived nurselike cells (NLC).
These stromal cells establish chemokine gradients, such as CXCL12 and CXCL13 gradients that
attract CLL cells via the corresponding G-protein-coupled chemokine receptors, CXCR4 and
CXCR5, respectively. Adhesion molecules on the CLL cells, such as CD49d (VLA-4), cooperate
with chemokine receptors during this process. NLC also express BAFF and APRIL, as well as
CD31 for activation of respective ligands on the leukemia cells, promoting growth and survival of
the CLL cells
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and retention of the lymphocytes via chemokine gradients (Campbell et al. 1998).
This process, referred to as “tissue homing,” is an integral part of immune sur-
veillance and function of the immune system. Specific to B cells is their localization
in germinal centers during adaptive immune responses, where somatic hypermu-
tation and clonal selection occur within distinct regions called dark zone (DZ) and
light zone (LZ). PI3Kδ inhibition with idelalisib significantly reduces CLL cell
migration in response to CXCL12 and CXCL13, as well as high CXCL13 plasma
levels in patients treated with idelalisib (Hoellenriegel et al. 2011).
Normal mechanisms of B cell trafficking and tissue homing are largely preserved
in CLL B cells. Blood CLL cells express high levels of CXCR4 (Burger et al.
1999), which are downregulated in tissues by its ligand CXCL12 (Burger et al.
1999). This effect can be used to distinguish proliferating CXCR4dim CLL cells in
CXCL12-abundant tissues (bone marrow, lymph nodes) from CXCR4high CLL
cells from blood (Bennett et al. 2007; Calissano et al. 2009). CXCR5 is another
chemokine receptor expressed at high levels on CLL cells, which controls access of
CLL cells to monocyte-derived “nurselike cells” (NLC) (Burkle et al. 2007) and
follicular dendritic cells (FDC) (Heinig et al. 2014). In turn, CXCR5-mediated
contact to FDC provides proliferative stimuli to the CLL cells (Heinig et al. 2014).
CLL cells also can stimulate stromal cells through lymphotoxin-β-receptor acti-
vation, resulting in CXCL13 secretion and remodeling of the stromal cell com-
partment, linking CLL cell homing with shaping of survival niches and access to
proliferation stimuli.
Another layer of complexity is added by the fact that activated CLL cells also
secrete chemokines (CCL3, CCL4, and CCL22) which further shape the cellular
composition of the tissue microenvironment (Burger et al. 2009; Ghia et al. 2002).
CCL3 and CCL4 are generally secreted by macrophages, dendritic cells, B and T
lymphocytes, and function as chemoattractants for monocytes and lymphocytes
(Schall et al. 1993). Previous studies established that CCL3 is a key response gene
upregulated in normal and neoplastic B cells in response to BCR signaling (Burger
et al. 2009; Eberlein et al. 2010; Herishanu et al. 2011; Krzysiek et al. 1999) and
repressed by Bcl-6 (Shaffer et al. 2000). CLL cells upregulate and secrete CCL3
and CCL4 in response to BCR stimulation and in coculture with NLC (Burger et al.
2009), a model system resembling the lymphatic tissue microenvironment (Burger
et al. 2000, 2009). High CCL3 plasma concentrations are a robust, independent
prognostic marker in CLL (Sivina et al. 2011). This BCR- and NLC-dependent
induction of CCL3 and CCL4 is sensitive to inhibition of BCR signaling, using
SYK (Hoellenriegel et al. 2012; Quiroga et al. 2009), BTK (Burger et al. 2014;
Ponader et al. 2012), or PI3Kδ (Hoellenriegel et al. 2011) inhibitors, both in vitro
and in vivo. Based on the postulated function of B-cell-derived CCL3 in normal
immune responses, increased CCL3 secretion by CLL cells may cause attraction
and homing of accessory cells to the malignant B cells in the tissue microenvi-
ronments (Burger et al. 2009; Zucchetto et al. 2009). It is well recognized that CLL
cells in the proliferative compartment are interspersed with T cells (Ghia et al. 2002;
Patten et al. 2008) and cells of monocyte/macrophage lineage, termed NLC (Burger
et al. 2009). Conceivably, CLL cell-derived CCL3 may attract these cells, creating a
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favorable microenvironment which allows CLL cells to interact with T cells and
NLC to receive survival and proliferation signals. This is supported by in vitro
(Krzysiek et al. 1999) and in vivo (Bystry et al. 2001; Castellino et al. 2006) studies
which indicated that normal B cell activation within lymphoid tissues results in
CCL3 and CCL4 secretion, leading to the recruitment of CCR5+ regulatory T cells
for cognate interactions with B cells and antigen-presenting cells (APCs) (Bystry
et al. 2001; Castellino et al. 2006). In ongoing clinical trials with new agents
targeting the BCR pathway (SYK, BTK, and PI3Kδ inhibitors), increased levels of
CCL3 and CCL4 rapidly normalized after initiation of therapy with the BTK
inhibitor ibrutinib (Burger et al. 2014; Ponader et al. 2012) and the PI3Kδ inhibitor
idelalisib (Hoellenriegel et al. 2011) (Table 1).
4.3 Role of PI3K in T Cells in CLL
Characterization of preclinical effects of the PI3Kδ inhibitor idelalisib focused on
CLL cells (Herman et al. 2010; Hoellenriegel et al. 2011), rather than on other
immune cells, such as T cells. However, the idelalisib side effect profile in CLL
patients, especially cases of pneumonitis and late-onset diarrhea, points toward
other immune-mediated effects (Coutre et al. 2015). T-cell-mediated inflammatory
bowel disease seen in the PI3Kδ kinase dead-mouse model may be related to
reduced regulatory T cell (Treg) function (Okkenhaug et al. 2002; Patton et al. 2006)
or increased macrophage response to gut microbiota (Steinbach et al. 2014; Uno
et al. 2010). The idelalisib-prescribing information contains a warning for severe
diarrhea or colitis, hepatotoxicity, pneumonitis, and intestinal perforation. An early
type of diarrhea, which generally occurs within the first 8 weeks, is typically mild
and tends to be self-limiting. A second type of diarrhea tends to occur relatively
late, is clinically often more complicated, and shows histologic signs of lympho-
cytic colitis that are reminiscent of those seen in PI3Kδ knockout mice (Coutre et al.
2015; Okkenhaug et al. 2002). Hence, these clinical observations suggest
Table 1 Selected PI3K, SYK, and BTK inhibitors in B cell malignancies (phase 2 and later, most
advanced trial listed)
Disease Target Drug Stage Study
CLL/SSL
PI3Kδ Idelalisib Approved NCT01539512
PI3Kδ/γ Duvelisib Phase 3 NCT02004522
BTK Ibrutinib Approved NCT01578707
iNHL PI3Kδ Idelalisib Approved NCT01282424
PI3Kδ/γ Duvelisib Phase 2 NCT01882803
DLBCL SYK Fostamatinib Phase 2 NCT01499303
Multiple B cell
malignancies
SYK Entospletinib Phase 2 NCT01799889
SYK + PI3Kδ Entospletinib + idelalisib Phase 2 NCT01796470
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that PI3Kδ inhibition in CLL patients has effects on T cell subsets, triggering
inflammatory reactions in a subset of patients. On the other hand, it is tempting to
speculate that some of the beneficial clinical activity of idelalisib in CLL may be
related to breaking Treg-cell-mediated immune tolerance to the CLL cells, as
recently described in mouse models of solid tumors (Ali et al. 2014). In addition,
there is evidence that Th1 cells can support CLL activation and proliferation
(Burgler et al. 2015; Os et al. 2013) and PI3Kδ inhibition can suppress Th1
responses (Okkenhaug et al. 2006; Soond et al. 2010). None of these issues have yet
been experimentally addressed in the context of CLL, and therefore, studies of the
effects of idelalisib on T cell subsets in CLL patients should become an important
part of future correlative studies.
4.4 Targeting BTK and PI3Kδ: Redundant or Synergistic?
Effects of BTK and PI3Kδ inhibition on BCR signaling and B cell migration and
adhesion are similar in terms of their effects on calcium signaling and gene regu-
lation (Fruman et al. 2000); however, the kinases diverge at the level of Akt and
Foxo which are primarily regulated by PI3K (Fig. 1). Hence, the phenotype and
functional defects within the B cell compartment of BTK- or PI3Kδ-deficient mice
are similar, but with some key differences (Okkenhaug et al. 2002; Ponader and
Burger 2014; Suzuki et al. 2003b). Idelalisib and ibrutinib have multiple similarities
in terms of anti-CLL activity. First, they both induce rapid and robust reduction in
lymphadenopathy, together with a transient redistribution of CLL cells into the
peripheral blood, which over time, while patients are receiving continuous kinase
inhibitor therapy, improves and resolves in many patients, especially when given
together with other agents, such as anti-CD20 mAbs (Burger et al. 2014; Furman
et al. 2014). These clinical responses are thought to be due to dual effects of these
kinase inhibitors on migration and tissue homing of the CLL cells on the one hand,
and on proliferation and survival of the leukemia cells on the other hand. These
similarities between BTK and PI3Kδ inhibition raise the question whether com-
binations of drugs that target these enzymes, such as idelalisib and ibrutinib, would
have any benefit or be redundant. Besides the obvious disadvantage of high
treatment costs, such combinations likely have off target effects on the immune
system in general, and on T cell in particular that currently are difficult to predict
and that could be either beneficial or toxic.
At this time, treatment with these kinase inhibitors is continuous and indefinite in
patients who benefit with sustained responses, although a subset of patients treated
with ibrutinib develop specific resistance and may benefit from switching to idel-
alisib. Whether similar resistance to idelalisib will develop, prompting a switch to
ibrutinib, remains to be seen. The adverse effect profile or idelalisib and ibrutinib
are also different. While a significant proportion of patients on idelalisib develop
colitis (Coutre et al. 2015), some ibrutinib patients develop atrial fibrillation (Byrd
et al. 2014). With time, it may become possible to stratify patients who are more
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likely to benefit from BTK or PI3Kδ inhibitors. It also remains possible that
next-generation inhibitors will be associated with fewer side effects.
The fact that BTK and PI3Kδ inhibitions typically induce partial remissions with
substantial residual disease (Byrd et al. 2013; Furman et al. 2014), even after years
of continuous therapy (Byrd et al. 2015), suggests that additional therapeutic
intervention, such as immune-mediated therapy, is necessary for disease eradication
that would allow therapy discontinuation. Immune-modulatory effects of ibrutinib
(Sagiv-Barfi et al. 2015) and PI3Kδ inhibition (Ali et al. 2014), resulting in res-
toration of cytotoxic T cell function and T-cell-mediated tumor regression, are the
most recent exciting effects of this class of agents. Ibrutinib’s T cell modulatory
effects are mediated through a shift in the balance between Th1 and Th2 T cells by
inhibition of ITK, an essential enzyme in Th2 T cells (Dubovsky et al. 2013;
Sagiv-Barfi et al. 2015). PI3Kδ inhibition, on the other hand, disables regulatory T
cells and thereby unleashes CD8-positive cytotoxic T cells (Ali et al. 2014). These
immune-modulatory effects could support each other when combined and could
result in deeper remissions or potentially even in immune-mediated disease eradi-
cation. Carefully designed trials with correlative studies that address these mech-
anistic questions will help to evaluate the risks and therapeutic potential of
combined BTK and PI3Kδ inhibition.
5 Perspective: Targeting PI3K in Other B Cell Cancers
In this chapter, we have focused on PI3Kδ signaling in normal B cells and the
relevance of this to the treatment of CLL with the recently approved drug idelalisib
—the first PI3K inhibitor to be approved for clinical use. Idelalisib is also licensed
for treatment of indolent non-Hodgkins lymphoma, and with time other cancers
may also be found to respond. It is worth noting, for instance, that certain subtypes
of DLBCL have a BCR activation profile and it has been suggested that these may
benefit from PI3K inhibition. It has also been shown recently that a subset of acute
lymphoblastic leukemia may benefit from PI3K inhibition (Geng et al. 2015).
However, it is possible that immature B cell leukemia may require dual inhibition of
PI3Kδ and PI3Kα, reflecting the redundant role of these isoforms during early B
cell development and tonic BCR signaling (Ramadani et al. 2010). It has also been
suggested that dual PI3Kα and PI3Kδ inhibition may be required for inhibition in
mantle cell lymphoma (Iyengar et al. 2013).
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